HealthBeacon PLC HealthBeacon - HBCN - Launches HB Smart Pills™ Solution

Healthbeacon

08/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220908:nRSH6867Ya&default-theme=true

RNS Number : 6867Y  HealthBeacon PLC  08 September 2022

HealthBeacon launches HB Smart Pills™ Solution

 

Boston, 08 September 2022: HealthBeacon plc ("HealthBeacon"), the leading
digital therapeutics company for injectable medications, has extended its
platform to manage complex and critical pill regimens with the launch of its
new HB Smart Pills Management System ("HB Smart Pills").

 

The announcement will be made at HealthBeacon's inaugural Vision Event in
Boston later today where CEO Jim Joyce will share the Company's vision from
2022 to 2024, with an interactive product showcase of the Company's medication
adherence technology following talks by global industry leaders and patient
advocates on healthcare innovation using digital health technology.

 

The launch follows the Company's recent addition of the integrated HB Smart
Scale and the partnership with the American Pharmacists Association
Foundation.

 

The HB Smart Pills solution is an elegant device designed to fit into a
patient's home managing up to nine oral medications and integrates seamlessly
with the Company's existing technology platform. The innovative HB Smart Pills
solution notifies the patient when prescription refills are required and
records visual images of pill containers to ascertain medication adherence.

 

Adherence to pill regimes is a significant challenge for people with chronic
illnesses managing multiple critical medications at different intervals, with
up to 60% of patients globally failing to take their medications as
prescribed. The U.S. oral solid dosage pharmaceutical market was valued at
$214.1 billion in 2021 and is expected to exceed $420.3 billion by 2032.

 

Expanding the Company's product offering to now include Pill Management
enables HealthBeacon to continue to roll out its technology and services
through pharmaceutical companies, specialty pharmacy and governments,
deepening its existing relationships and increasing its customer base.

 

HB Smart Pills will be available through the company's existing distribution
channels in 2023.  To learn more contact HBSmartPills@HealthBeacon.com
(mailto:hbsmartpills@healthbeacon.com)

 

Commenting, HealthBeacon CEO and co-founder, Jim Joyce, said: "Today's launch
of the HB Smart Pills at our inaugural Vision Event is a significant milestone
for the Company on its path to becoming the world's leading digital
therapeutics platform for patients managing medications in the home.
Broadening our product offering and connecting HealthBeacon members to better
health with digitally enabled solutions is an important step on this journey.
The recent new product announcements of the HB Smart Pills and integrated
Smart Scale build on the significant momentum in the business as leading
pharma companies and health systems adopt our technology."

 

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

                                                (mailto:Investor.Relations@HealthBeacon.com)
 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Paul Clifford                                    +353 (0) 87 327 2161

 

Ends

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company operates across Europe, North America and the United Kingdom and
employs more than 70 people and has obtained more than 30 design and utility
patents. The Company's mission is to become the world's leading digital
therapeutics platform for patients managing medications in the home.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEEANNXEFFAEFA